SCOLR Pharma, Inc. Reports Third Quarter 2009 Financi...(------ Total liabilities ...),Health

Date:11/6/2009

------ Total liabilities 931,169 1,328,524 Commitments and Contingencies Stockholders' Equity Preferred stock, authorized 5,000,000 shares, $.01 par value, none issued or outstanding - - Common stock, authorized 100,000,000 shares, $.001 par value 41,098,270 and 41,130,270 issued and outstanding as of September 30, 2009, and December 31, 2008, Respectively 41,098 41,130 Additional paid-in capital 72,138,140 71,255,901 Accumulated deficit (69,037,613) (63,975,066) ----------- ----------- Total stockholders' equity 3,141,625 7,321,965 ----------- ----------- $4,072,794 $8,650,489 =========== ===========

                                 SCOLR Pharma, Inc.

                        CONDENSED STATEMENTS OF OPERATIONS
                                    (Unaudited)


                                Three months ended     Nine months ended
                                   September 30,           September 30,
                                 2009        2008        2009        2008
                                 ----        ----        ----        ----
    Revenues
     Royalty income            $261,651    $236,308    $664,212    $781,435
                              ---------     -------   ---------   ---------
        Total revenues          261,651     236,308     664,212     781,435

    Operating expenses
     Marketing and selling       54,351     116,840     200,402     545,579
     Research and development   572,189   2,307,103   
'/>"/>
SOURCE  SCOLR Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 
Related medicine technology :

1. SCOLR Pharma Announces Completion of Patient Enrollment and Dosing for Pivotal Clinical Trial Evaluating Extended Release Ibuprofen
2. SCOLR Pharma, Inc. Reports Third Quarter 2008 Financial Results
3. Victory Pharma, Inc. Reports MGX006 Enters Into Pivotal Development Program
4. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
5. FluoroPharma, Inc. to Report Preclinical Data on Alzheimers Disease and Prostate Cancer PET Imaging Agents
6. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
7. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
8. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
9. Strativa Pharmaceuticals Development Partner, BioAlliance Pharma, Presents Phase III Study Results of Miconazole Lauriad(R) for the Treatment of Oropharyngeal Candidiasis
10. Northern Light Adds 4,000 Bio-Pharma, Health Sciences and General Business News and Journal Sources from EBSCO Publishing
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound